Third Harmonic Bio is a biopharmaceutical company with a singular purpose: To advance a new treatment approach for people living with inflammatory diseases, which can take a significant toll on health and well-being.
We are currently focused on developing THB335, a highly selective, oral small molecule wild-type KIT inhibitor.
THB335 is expected to enter clinical trials during the first half of 2024. We intend to pursue development of TBH335 for chronic urticaria, a dermatologic disease affecting up to 1% of the population that is driven by mast cell activation and results in red, itchy, painful welts or hives that can severely impact patients’ quality of life, as well as for other mast cell-mediated inflammatory diseases.
Third Harmonic Bio is led by an executive team with a proven track record of building great companies, developing impactful medicines, and delivering value to their patients, employees, and shareholders.
Edward R. Conner, M.D.
Adrian S. Ray, Ph.D.
David Bonita, M.D.
Mark Iwicki (Chairman)
Martin Seidel, Ph.D.
Thomas M. Soloway
1700 Montgomery Street, Suite #210
San Francisco, CA 94111
130 Prospect Street,
Cambridge, MA 02139